GW&K Investment Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.1M Sell
2,129,421
-61,337
-3% -$592K 0.24% 155
2026
Q1
$16.3M Sell
2,190,758
-48,009
-2% -$505K 0.14% 224
2025
Q4
$26.3M Buy
2,238,767
+155,882
+7% +$1.68M 0.23% 174
2025
Q3
$16.1M Sell
2,082,885
-392,091
-16% -$2.75M 0.14% 224
2025
Q2
$18.1M Buy
2,474,976
+2,245,210
+977% +$18.1M 0.16% 210
2025
Q1
$2.18M Sell
229,766
-3,526
-2% -$44K 0.02% 306
2024
Q4
$3.85M Sell
233,292
-19,555
-8% -$304K 0.03% 289
2024
Q3
$3.73M Buy
252,847
+35,669
+16% +$558K 0.03% 282
2024
Q2
$3.01M Sell
217,178
-10,745
-5% -$152K 0.03% 290
2024
Q1
$3.58M Sell
227,923
-7,275
-3% -$112K 0.03% 285
2023
Q4
$3.81M Sell
235,198
-10,475
-4% -$171K 0.04% 278
2023
Q3
$3.02M Sell
245,673
-4,637
-2% -$69K 0.03% 290
2023
Q2
$4.02M Buy
250,310
+365
+0.1% +$6.01K 0.04% 285
2023
Q1
$4.35M Sell
249,945
-89,905
-26% -$1.28M 0.04% 275
2022
Q4
$3.14M Buy
339,850
+129,145
+61% +$1.2M 0.03% 289
2022
Q3
$1.81M Buy
+210,705
New +$2.09M 0.02% 305

Other funds holding NEO

GW&K Investment Management's NEO Position: Q2 2026 in Review

GW&K Investment Management reduced its NeoGenomics (NEO) stake by 2.8% in Q2 2026, selling an estimated $592K and leaving 2,129,421 shares worth $31.1M. The position accounts for 0.24% of the portfolio, ranked #155.

GW&K Investment Management first reported a position in NEO in Q3 2022 and has held it in 16 quarters since. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • GW&K Investment Management held 2,129,421 shares of NeoGenomics worth $31.1M as of Q2 2026.
  • GW&K Investment Management sold 61,337 NeoGenomics shares in Q2 2026, an estimated $592K.
  • NeoGenomics made up 0.24% of GW&K Investment Management's portfolio in Q2 2026, its #155 holding.
  • GW&K Investment Management first reported a position in NeoGenomics in Q3 2022 and has held it in 16 quarters since.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.